民和股份(002234.SZ):1月商品代雞苗銷售收入同降42.66%、環增38.17%
格隆匯2月11日丨民和股份(002234.SZ)披露2022年1月份雞苗銷售情況簡報,公司2022年1月銷售商品代雞苗2384.20萬隻,同比變動5.30%,環比變動87.81%;銷售收入2721.88萬元,同比變動-42.66%,環比變動38.17%。
公司商品代雞苗銷量環比上升87.81%,主要原因是上月因停孵影響,產量較低,1月開始商品代雞苗逐步正常生產銷售;公司商品代雞苗銷售收入同比下降42.66%,主要原因是本期雞苗銷售均價較低所致;公司商品代雞苗銷售收入環比上升38.17%,主要原因是本期雞苗銷量增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.